At the end of 5 years, NICE will review all the extra information they have gathered (including all the clinical and Quality of Life data) and look again at how well Translarna works in patients. If at the end of the 5 year MAA, NICE no longer recommends Translarna for NHS funding, then NHS England funded treatment would need to stop.

However, if at the end of the 5 year MAA, NICE recommends Translarna for further NHS funding, then it will continue to be funded in England according to the arrangements between NICE and NHS England at that time.

If you would like any more information about Translarna or the MAA process, please contact Shelley Simmonds, CEO Action Duchenne [email protected] .